ArticleScientific reports2021
Role of hepatitis D virus infection in development of hepatocellular carcinoma among chronic hepatitis B patients treated with nucleotide/nucleoside analogues.
Article in Scientific reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 32 citations in OpenAlex.
- Diagnostic Efficacy of Serological Antibody Detection Tests for Hepatitis Delta Virus: A Systematic Review and Meta-Analysis.Viruses · 2023Pooled it
- Hepatitis D Virus: Enigmas and Gaps of Knowledge.Viruses · 2026Review
- Knowledge, attitude, and practice toward antiviral treatment of chronic hepatitis B among patients.Scientific reports · 2025Article
- Identifying Risk Factors for Hepatocellular Carcinoma in Patients With Delta Hepatitis: A Prognostic Study.Journal of viral hepatitis · 2025Article
- Air pollution causes abnormal alanine aminotransferase levels in patients with chronic hepatitis B.Journal of the Chinese Medical Association : JCMA · 2025Article
- Multisociety consensus recommendations on hepatitis delta virus infection.Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology Association · 2025Article
- Review
- Hepatitis Delta Virus and Hepatocellular Carcinoma.Pathogens (Basel, Switzerland) · 2024Review
- Air pollution as a potential risk factor for hepatocellular carcinoma in Taiwanese patients after adjusting for chronic viral hepatitis.Journal of the Chinese Medical Association : JCMA · 2024Article
- Review of Related Factors for Persistent Risk of Hepatitis B Virus-Associated Hepatocellular Carcinoma.Cancers · 2024Review
- Molecular and Clinical Features of Hepatocellular Carcinoma in Patients with HBV-HDV Infection.Journal of hepatocellular carcinoma · 2023Review
- Hepatitis Delta: Current Knowledge and Future Directions.Gastroenterology & hepatology · 2022Article
- Molecular epidemiology and clinical characteristics of hepatitis D virus infection in Canada.JHEP reports : innovation in hepatology · 2022Article
- Hepatocellular Carcinoma in Chronic Viral Hepatitis: Where Do We Stand?International journal of molecular sciences · 2022Review
- Beyond the Usual Suspects: Hepatitis E Virus and Its Implications in Hepatocellular Carcinoma.Cancers · 2021Review
- The Prevalence and Serological Association of Hepatitis D Virus Genotypes in Taiwan.Pathogens (Basel, Switzerland) · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
24 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatitis D virus (HDV) infection increases the risk of hepatocellular carcinoma (HCC) in the natural course of chronic hepatitis B (CHB) patients. Its role in patients treated with nucleotide/nucleoside analogues (NAs) is unclear. We aimed to study the role of hepatitis D in the development of HCC in CHB patients treated with NAs. Altogether, 1349 CHB patients treated with NAs were tested for anti-HDV antibody and RNA. The incidence and risk factors of HCC development were analyzed. Rates of anti-HDV and HDV RNA positivity were 2.3% and 1.0%, respectively. The annual incidence of HCC was 1.4 per 100 person-years after a follow-up period of over 5409.5 person-years. The strongest factor association with HCC development was liver cirrhosis (hazard ratio [HR]/95% confidence interval [CI] 9.98/5.11-19.46, P < 0.001), followed by HDV RNA positivity (HR/ CI 5.73/1.35-24.29, P = 0.02), age > 50 years old (HR/CI 3.64/2.03-6.54, P < 0.001), male gender (HR/CI 2.69/1.29-5.60, P: 0.01), and body mass index (BMI, HR/CI 1.11/1.03-1.18, P = 0.004). The 5-year cumulative incidence of HCC was 7.3% for patients with HDV RNA negativity compared to that of 22.2% for patients with HDV RNA positivity (P = 0.01). In the subgroup of cirrhotic patients, the factors associated with HCC development were HDV RNA positivity (HR/CI 4.45/1.04-19.09, P = 0.04) and BMI (HR/CI 1.11/1.03-1.19, P = 0.01). HDV viremia played a crucial role in HCC development in CHB patients who underwent NA therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.